European Archives - Page 17 of 1322 - European Medical Journal

The Evolving Biomarker Landscape in GI Cancers

First-Line Advances in TNBC: Datopotamab Deruxtecan and Sacituzumab Govitecan at ESMO 2025

THIS YEAR, the field of triple-negative breast cancer (TNBC) has witnessed significant advancements in the first line…

Nutrition in Oncology

During this symposium at the European Society of Medical Oncology (ESMO) Congress 2025, leading experts in oncology and nutrition…

AI and Cancer Care

AI WAS a highlight of the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany, with sessions focused…

New Horizons in Anal Cancer and CRC

Anal and colorectal cancers are complex gastrointestinal malignancies that continue to pose therapeutic and diagnostic challenges…

The New Frontiers of Personalised Cancer Prevention

THIS YEAR, the highly anticipated European Society for Medical Oncology (ESMO) Congress 2025 was held in Berlin, Germany…

Multi-omics Insights for Biomarkers in NSCLC

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality worldwide…

Immune Checkpoint Inhibitor-Associated Hydropneumothorax

Immune checkpoint inhibitors (ICI) are monoclonal antibodies capable of reversing cancer-induced immune evasion and promoting tumour death…

Recurrent Plexiform Neurofibroma with KRAS and AKT1 Mutations

Plexiform neurofibromas (PNF) are benign, often infiltrative tumours of the peripheral nerve sheath classically linked to neurofibromatosis…

Favorable Response of Unresectable Giant Pinealoblastoma

The pineal gland is a small endocrine gland that regulates the circadian rhythm by secreting melatonin. Tumours of the pineal region…